新非小细胞肺癌标志物CYFRA 21-1测定与临床评价

Clinical measurement and evaluation of CYERA21 1 as a new tumor marker for non small cell lung cancer

目的：研究新癌标ＣＹＥＲＡ２１－１ 对非小细胞肺癌，特别是鳞癌在临床诊断和予后监测上的意义。方法：测定于１９９６ 年至１９９７ 年４ 月间住院的９２ 例患者（肺癌６４ 例，良性肺疾病２８ 例）的血清ＣＹＥＲＡ２１－１ 和ＣＥＡ的值，并比较肺癌的不同组织类型、临床分期和治疗前后的差异。结果：血清ＣＹＥＲＡ２１－１ 和ＣＥＡ 的阳性率在肺癌中分别为４２．１９％ 和３４．３５％ 显著地高于良性肺疾病组， ＣＹＥＲＡ２１－１ 值和阳性率在肺鳞癌显著地高于腺癌组（Ｐ＜０．０１），肺鳞癌Ⅳ期高于Ⅲ期（Ｐ＜ ０．０５），治疗后值下降。结论：血清ＣＹＥＲＡ２１－１ 对肺癌、特别是对鳞癌是一个有用的诊断和监测标记物。

Objective:This study tried to investigate the effect or serum CYERA21 1 as a new lung cancer marker in clinical diagnosis and monitoring the prognosis of non small cell lung cancer (NSCLC), especially in squamous cell cancer (SQC).Methods:The values of serum CYERA21 1 and CEA (Carcinoembryonic antigen) were determined in 92 patients with lung cancer (64 cases) and benigh lung diseses (28 cases) admitted in our hospital from August 1996 to April 1997, and compared the deference values of serum CYERA21 1 between different histological types, clinical stages before and after therapy of lung cancer. Results:The positive rates of serum CYERA21 1 and CEA in lung cancer were 42.19% and 34.53% respectively significantly higher than in benign lung diseses; the values or positive rates of serum CYERA21 1 in SQC were higher significantly than adenocarcinoma ( P <0 01), higher in stage Ⅳ than stage Ⅲ of SQC ( P <0 05), decreaed after treatment in NSCLC. Conclusion:The serum CYERA21 1 is a useful diagnotic and monitoring tumor marker in lung cancer particulaely for squamour cell lung cancer.